In the wake of its takeover of Shire, Japanese drugmaker Takeda (TYO: 4502) has announced it has filed paperwork for the issuance of a 500 billion yen ($4.5 billion) bond.
The company has significantly increased its debt commitments since agreeing terms, in May 2018, to buy the Ireland-headquartered rare disease drugmaker for £46 billion ($62 billion). The latest move follows the issuance of $5.5 billion of bonds in late 2018.
Takeda says that it does not intend to increase its overall level of borrowing, but may continue refinancing to arrange the structure of its debts in an optimal way.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze